Literature DB >> 31049984

Coronary artery calcification in middle-aged women with premature ovarian insufficiency.

Marlise N Gunning1, Cindy Meun2, Bas B van Rijn2,3, Angela H E M Maas4, Laura Benschop2, Arie Franx3, Eric Boersma5, Ricardo P J Budde6, Yolande Appelman7, Cornelis B Lambalk8, Marinus J C Eijkemans1,9, Birgitta K Velthuis10, Joop S E Laven2, Bart C J M Fauser1.   

Abstract

OBJECTIVE: Women with premature ovarian insufficiency (POI) enter menopause before age 40. Early menopause was associated with increased risk for coronary artery disease (CAD), death from cardiovascular disease and all-cause mortality. We compared the prevalence of CAD between middle-aged women on average 10 years following the initial POI diagnosis, with a population-based cohort.
DESIGN: Cross-sectional case-control study. PARTICIPANTS: Women from two Dutch University Medical Centers above 45 years of age previously diagnosed with POI (n = 98) were selected and compared with age- and race-matched controls from the Multi-Ethnic Study of Atherosclerosis (MESA). MEASUREMENTS: The primary outcome was detectable coronary artery calcium (CAC) determined by coronary computed tomography (CCT).
RESULTS: Women with POI had significantly higher blood pressure, cholesterol and glucose, despite lower BMI compared to controls. Similar proportions of detectable CAC (CAC score >0 Agatston Units) were observed in women with POI and controls (POI n = 16 (16%), controls n = 52 (18%), P = 0.40 and Padj  = 0.93). In women with POI separately, we were not able to identify associations between CVD risk factors and CAC. The following CVD risk factors in controls were positively associated with CAC: age, diabetes mellitus, hypertension and LDL cholesterol. HRT use was negatively associated with CAC in controls.
CONCLUSIONS: The presence of CAC did not differ significantly in women with POI around 50 years of age, compared to an age- and race-matched control group. We observe no increased calcified coronary disease in POI patients, despite the presence of unfavourable cardiovascular risk factors in these women.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  POI; cardiovascular; coronary artery calcium score; menopause; reproductive disorder; risk factor

Mesh:

Year:  2019        PMID: 31049984     DOI: 10.1111/cen.14003

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

1.  Association of Premature Menopause With Coronary Artery Calcium: The CARDIA Study.

Authors:  Priya M Freaney; Lucia Petito; Laura A Colangelo; Cora E Lewis; Pamela J Schreiner; James G Terry; Melissa Wellons; Catherine Kim; Jamal S Rana; Donald M Lloyd-Jones; Norrina B Allen; Sadiya S Khan
Journal:  Circ Cardiovasc Imaging       Date:  2021-11-11       Impact factor: 7.792

2.  Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists.

Authors:  Angela H E M Maas; Giuseppe Rosano; Renata Cifkova; Alaide Chieffo; Dorenda van Dijken; Haitham Hamoda; Vijay Kunadian; Ellen Laan; Irene Lambrinoudaki; Kate Maclaran; Nick Panay; John C Stevenson; Mick van Trotsenburg; Peter Collins
Journal:  Eur Heart J       Date:  2021-03-07       Impact factor: 29.983

3.  Clinical Observation on the Improvement of Serum Sex Hormone and Ovarian Function in Premature Ovarian Failure Patients with Deficiency-Cold Syndrome by Combining Wenjing Decoction with Tiaobu Chongren Acupuncture and Moxibustion.

Authors:  Anlun Yi; Xianbing Qin; Zhiyin Du; Tingling Wang; Fang Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-11       Impact factor: 2.629

Review 4.  Autoimmune Diseases in Patients with Premature Ovarian Insufficiency-Our Current State of Knowledge.

Authors:  Anna Szeliga; Anna Calik-Ksepka; Marzena Maciejewska-Jeske; Monika Grymowicz; Katarzyna Smolarczyk; Anna Kostrzak; Roman Smolarczyk; Ewa Rudnicka; Blazej Meczekalski
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.